Do have pemphigus?

The PEGASUS study: a clinical trial to assess a new drug for pemphigus

The purpose of this study is to compare the safety and effectiveness of PRN1008 as a treatment for pemphigus vulgaris (PV) and pemphigus foliaceus (PF) when taken with a corticosteroid and compare this to the safety and effectiveness of corticosteroid alone. 

PRN1008 is an investigational drug developed by the study sponsor, Principia for the treatment of autoimmune and inflammatory diseases, such as pemphigus. PRN1008 is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor.  BTK is an enzyme that plays a crucial role in B-cell development, a type of white blood cell that is involved in the immune system, and in the white blood cells’ role in diseases like PV or PF.

Enrolment status: Open to recruitment

Who can take part

Inclusion criteria

  • Age 18-80
  • Diagnosis of moderate to severe, newly or relapsing PV or PF

Exclusion criteria

  • Paraneoplastic pemphigus

  • A history of malignancy of any type, except for non-melanoa skins cancers or in situ cervical cancer within 5 years

  • Pregnant or lactating women

What is involved for you

  • 68 weeks total
  • blood/urine samples
  • chest x-ray
  • weight
  • blood pressure
  • injections
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2018.349
Annette Phemister
03 9342 4531